Trial Profile

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
Indications Urogenital cancer
Focus Therapeutic Use
Acronyms PemCab

Most Recent Events

28 Nov 2024 Status changed from active, no longer recruiting to completed.
11 Jun 2024 Planned End Date changed from 31 May 2024 to 31 May 2025.
18 Mar 2024 Planned End Date changed from 17 May 2026 to 31 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com